# HIV Treatment (2023-2025)

> **15 papers on long-acting injectables, integrase inhibitors, and novel antiretrovirals.**

---

## Papers in This Section

| ID | Title | Year |
|:---|:------|:-----|
| TRT-001 | Lenacapavir FDA Approval for PrEP | 2025 |
| TRT-002 | PURPOSE 1 Trial: 100% HIV Prevention in Women | 2024 |
| TRT-003 | PURPOSE 2 Trial: 96% Prevention in MSM/Trans | 2024 |
| TRT-004 | WHO Recommends Injectable Lenacapavir | 2025 |
| TRT-005 | Once-Yearly Lenacapavir Phase 1 Trial | 2025 |
| TRT-006 | Islatravir + Lenacapavir Once-Weekly Oral | 2024 |
| TRT-007 | Doravirine/Islatravir Phase 3 Trial Results | 2024 |
| TRT-008 | VH4524184 Third-Generation INSTI Phase 1 | 2024 |
| TRT-009 | PASO-DOBLE: Dovato vs Biktarvy Head-to-Head | 2024 |
| TRT-010 | LATITUDE Trial: Cabenuva Superior Efficacy | 2024 |
| TRT-011 | Expanding Injectable Antiretrovirals Review | 2024 |
| TRT-012 | Islatravir Clinical Development for HIV and HBV | 2024 |
| TRT-013 | NRTI-Induced Neuropathy: Beyond Poly-gamma Hypothesis | 2024 |
| TRT-014 | Darunavir Resistance: High Genetic Barrier | 2024 |
| TRT-015 | FMO-Guided Design of Darunavir Analogs | 2024 |

---

## Key Themes

1. **Long-Acting Injectables**: Twice-yearly and weekly options
2. **Capsid Inhibitors**: Lenacapavir's novel mechanism
3. **Integrase Inhibitors**: Second and third-generation INSTIs
4. **Two-Drug Regimens**: Simplified treatment options
5. **Adherence**: Solutions for treatment challenges

---

*See [00_HIV_PAPERS_INDEX.md](../00_HIV_PAPERS_INDEX.md) for complete index.*
